Following clinical readouts in hypertension, biopharma firm Insmed announced plans for a $750 million follow-on public offering. The move underscores investor confidence after promising trial results. Additional financings were noted for Enliven, Cabaletta, Keymed, and ADC Therapeutics, alongside a planned IPO from Caris. Odyssey withdrew its listing. The wave of financings indicates active capital markets for biopharma amid mixed overall sector sentiment.